IPCA Laboratories Limited

As of June 30, 2026, IPCA Laboratories Limited carries a market capitalization of 431.55B, placing it among publicly traded companies globally. Its enterprise value stands at 431.55B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

IPCA Laboratories Limited's next confirmed earnings release is scheduled for November 9, 2026.

As of June 30, 2026, IPCA Laboratories Limited has 253.70M shares outstanding.

As of June 30, 2026, IPCA Laboratories Limited trades at a trailing price-to-earnings ratio of 32.95.

As of June 30, 2026, IPCA Laboratories Limited trades at an EV/EBITDA multiple of 20.12 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.26 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 25.14 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 431.55B versus a market cap of 431.55B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 4.34M in revenue per employee across its workforce of 23,351.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, IPCA Laboratories Limited recorded 4.35B in income tax expense. That works out to an effective tax rate of 23.98, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 18.14B, leaving 13.10B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, IPCA Laboratories Limited's stock has gained approximately 48.56% over the past 52 weeks. The 50-day moving average sits at 1,924.65, while the 200-day moving average is 1,660.22.

Over the twelve months ended June 30, 2026, IPCA Laboratories Limited generated 101.26B in revenue and converted that into 13.10B in net income, yielding earnings per share of 54.21. EBITDA reached 21.45B, while operating income came in at 18.03B.

Over the twelve months ended June 30, 2026, IPCA Laboratories Limited posted a gross margin of 71.08, reflecting its pricing power and cost economics. The operating margin of 17.80 and net profit margin of 12.94 provide insight into operational efficiency.

IPCA Laboratories Limited's most recent stock split took place on January 10, 2022 with a 1:2 split ratio.